Assertio Holdings, Inc. operates as a specialty pharmaceutical company in the United States. More Details
Excellent balance sheet and fair value.
Share Price & News
How has Assertio Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ASRT's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ASRT underperformed the US Pharmaceuticals industry which returned 12.2% over the past year.
Return vs Market: ASRT underperformed the US Market which returned 17.2% over the past year.
Price Volatility Vs. Market
How volatile is Assertio Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StIs Assertio Holdings (NASDAQ:ASRT) Using Debt Sensibly?
3 months ago | Simply Wall StThe Assertio Holdings (NASDAQ:ASRT) Share Price Is Down 96% So Some Shareholders Are Very Salty
4 months ago | Simply Wall StNews Flash: Analysts Just Made A Substantial Upgrade To Their Assertio Therapeutics, Inc. (NASDAQ:ASRT) Forecasts
Is Assertio Holdings undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ASRT ($0.67) is trading below our estimate of fair value ($8.59)
Significantly Below Fair Value: ASRT is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ASRT is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: ASRT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ASRT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ASRT is good value based on its PB Ratio (0.8x) compared to the US Pharmaceuticals industry average (3x).
How is Assertio Holdings forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ASRT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: ASRT is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ASRT's is expected to become profitable in the next 3 years.
Revenue vs Market: ASRT's revenue (1.5% per year) is forecast to grow slower than the US market (9.9% per year).
High Growth Revenue: ASRT's revenue (1.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ASRT's Return on Equity is forecast to be high in 3 years time
How has Assertio Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ASRT is currently unprofitable.
Growing Profit Margin: ASRT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ASRT is unprofitable, and losses have increased over the past 5 years at a rate of 22.1% per year.
Accelerating Growth: Unable to compare ASRT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ASRT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).
Return on Equity
High ROE: ASRT has a negative Return on Equity (-214.84%), as it is currently unprofitable.
How is Assertio Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: ASRT's short term assets ($135.5M) exceed its short term liabilities ($134.4M).
Long Term Liabilities: ASRT's short term assets ($135.5M) exceed its long term liabilities ($126.4M).
Debt to Equity History and Analysis
Debt Level: ASRT's debt to equity ratio (111.1%) is considered high.
Reducing Debt: ASRT's debt to equity ratio has reduced from 230.9% to 111.1% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable ASRT has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: ASRT is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 38.5% per year.
What is Assertio Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ASRT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ASRT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ASRT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ASRT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ASRT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Todd Smith (50 yo)
Mr. Todd N. Smith served as President, Chief Executive Officer and Director at Zyla Life Sciences since October 22, 2019. Mr. Smith serves as Chief Executive officer, President and Director at Assertio Hol ...
|Executive VP & CFO||1.75yrs||US$1.61m||0.11% |
|CEO, President & Director||0.33yr||no data||0.60% |
|Executive VP & COO||0.33yr||no data||0.23% |
|Media & Investor Relations Officer||no data||no data||no data|
|Senior VP||0.33yr||no data||0.18% |
|Vice President of Human Resources||0.33yr||no data||no data|
|Director of Human Resources||no data||no data||no data|
Experienced Management: ASRT's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.
|CEO, President & Director||0.33yr||no data||0.60% |
|Independent Director||16.83yrs||US$285.74k||0.21% |
|Independent Director||3.5yrs||US$290.59k||0.063% |
|Non-Executive Chairman||0.33yr||US$4.87m||0.39% |
|Independent Director||3.92yrs||US$270.65k||0.075% |
|Independent Director||1.58yrs||US$259.59k||0.013% |
|Lead Independent Director||0.33yr||no data||0.046% |
|Independent Director||1yr||US$206.75k||no data|
|Director||0.33yr||no data||0.046% |
Experienced Board: ASRT's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 32.9%.
Assertio Holdings, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Assertio Holdings, Inc.
- Ticker: ASRT
- Exchange: NasdaqGS
- Founded: 1995
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$71.311m
- Shares outstanding: 107.12m
- Website: https://www.assertiotx.com
Number of Employees
- Assertio Holdings, Inc.
- 100 South Saunders Road
- Suite 300
- Lake Forest
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ASRT||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Dec 1997|
|AH3||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Dec 1997|
Assertio Holdings, Inc. operates as a specialty pharmaceutical company in the United States. Its specialty pharmaceutical products include CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for treatin ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/01 00:01|
|End of Day Share Price||2020/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.